TNF and rheumatoid arthritis: Since a TNF inhibitor could reduce the pPDGFRαβ expression and pPDGFRαβ/CDH11 ratio, this drug could suppress FLSs with pPDGFRαβ expression, which is thought to have an aggressive phenotype that contributes to RA.